淋巴系统在一系列疾病的发展和进展中发挥着不可或缺的作用，这促使医学研究人员和临床医生设计、开发和利用先进的淋巴药物输送系统。在间质给药后，大多数治疗剂和分子通过引流毛细血管从组织中清除。然而，大于 20 kDa 或直径 10-100 nm 的大分子和递送系统通过引流淋巴管从间质转运，因为它们太大而无法穿过毛细血管内皮。小分子的淋巴吸收可以通过两种通用方法促进：与合成大分子构建体联合给药，或通过通过淋巴管从组织运输的内源性细胞或大分子载体搭便车。在本文中，我们回顾了后一种方法，即在皮下、肌肉或皮内注射后，通过搭便车内源性白蛋白转运途径将分子靶向淋巴。我们描述了与淋巴靶向相关的淋巴系统和白蛋白的特性，旨在搭便车白蛋白运输途径的药物和递送系统的特性以及如何进一步优化这些特性，最后介绍了白蛋白的当前应用和潜在的未来方向-针对淋巴管的搭便车方法。在本文中，我们回顾了后一种方法，即在皮下、肌肉或皮内注射后，通过搭便车内源性白蛋白转运途径将分子靶向淋巴。我们描述了与淋巴靶向相关的淋巴系统和白蛋白的特性，旨在搭便车白蛋白运输途径的药物和递送系统的特性以及如何进一步优化这些特性，最后介绍了白蛋白的当前应用和潜在的未来方向-针对淋巴管的搭便车方法。在本文中，我们回顾了后一种方法，即在皮下、肌肉或皮内注射后，通过搭便车内源性白蛋白转运途径将分子靶向淋巴。我们描述了与淋巴靶向相关的淋巴系统和白蛋白的特性，旨在搭便车白蛋白运输途径的药物和递送系统的特性以及如何进一步优化这些特性，最后介绍了白蛋白的当前应用和潜在的未来方向-针对淋巴管的搭便车方法。

"点击查看英文标题和摘要"

The lymphatic system plays an integral role in the development and progression of a range of disease conditions, which has impelled medical researchers and clinicians to design, develop and utilize advanced lymphatic drug delivery systems. Following interstitial administration, most therapeutics and molecules are cleared from tissues via the draining blood capillaries. Macromolecules and delivery systems >20 kDa in size or 10–100 nm in diameter are, however, transported from the interstitium via draining lymphatic vessels as they are too large to cross the blood capillary endothelium. Lymphatic uptake of small molecules can be promoted by two general approaches: administration in association with synthetic macromolecular constructs, or through hitchhiking on endogenous cells or macromolecular carriers that are transported from tissues via the lymphatics. In this paper we review the latter approach where molecules are targeted to lymph by hitchhiking on endogenous albumin transport pathways after subcutaneous, intramuscular or intradermal injection. We describe the properties of the lymphatic system and albumin that are relevant to lymphatic targeting, the characteristics of drugs and delivery systems designed to hitchhike on albumin trafficking pathways and how to further optimise these properties, and finally the current applications and potential future directions for albumin-hitchhiking approaches to target the lymphatics.